Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02637193 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects
A Phase 1 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT02637193 is a Phase 1 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 54 participants.
The verdict
NCT02637193, a Phase 1 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate a lack of effect of venlafaxine (Effexor XR) on QTc intervals relative to time matched placebo in healthy volunteers
Interventions
- DRUG Moxifloxacin
- DRUG Venlafaxine
- DRUG Drug - placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02637193
The ClinicalTrials.gov registry entry for NCT02637193 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT02637193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02637193 about?
NCT02637193 is a clinical study titled "A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects". The purpose of this study is to demonstrate a lack of effect of venlafaxine (Effexor XR) on QTc intervals relative to time matched placebo in healthy volunteers
What is the current status of trial NCT02637193?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2015-12. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02637193?
The interventions under investigation include: Moxifloxacin (DRUG), Venlafaxine (DRUG), Drug - placebo (DRUG).
Who is sponsoring clinical trial NCT02637193?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.